Last10K.com

Oncolytics Biotech Inc (ONCY) SEC Filing 20-F Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

ONCY Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ONCY Annual Reports

    20-F Annual Report March 2023
  • 20-F Annual Report March 2022
    • 20-F Annual Report March 2021
    20-F Annual Report March 2020
    20-F Annual Report March 2019

ONCY Corporate News

Oncolytics Biotech Inc

HISTORY TOOLS
CIK: 1129928 Ticker: ONCY

View differences made from one year to another to evaluate Oncolytics Biotech Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncolytics Biotech Inc.

Continue

Assess how Oncolytics Biotech Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncolytics Biotech Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 20-F Annual Report

Audit Information
Cover
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Equity (Deficit)
Consolidated Statements Of Financial Position
Consolidated Statements Of Financial Position (Parenthetical)
Consolidated Statements Of Loss And Comprehensive Loss
Additional Cash Flow Disclosures
Additional Cash Flow Disclosures (Tables)
Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)
Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)
Basis Of Financial Statement Presentation
Capital Disclosures
Capital Disclosures (Details)
Capital Disclosures (Tables)
Cash Equivalents
Cash Equivalents (Details)
Commitments
Commitments (Details)
Contingencies
Contingencies (Details)
Contract Liability
Contract Liability (Tables)
Contract Liability - Narrative (Details)
Contract Liability - Schedule Of Contract Revenues And Liabilities (Details)
Economic Dependence
Economic Dependence (Details)
Financial Instruments
Financial Instruments (Tables)
Financial Instruments - Narrative (Details)
Financial Instruments - Schedule Of Balances In Foreign Currencies (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Provision For Income Taxes (Details)
Income Taxes - Schedule Of Unrecognized Deferred Tax Assets (Details)
Income Taxes - Summary Of Non-Capital Losses (Details)
Income Taxes - Summary Of Non-Refundable Federal Investment Tax Credits (Details)
Incorporation And Nature Of Operations
Indemnification Of Officers And Directors
Leases
Leases (Tables)
Leases - Narrative (Details)
Leases - Right-Of-Use Assets And Lease Liabilities (Details)
Leases - Total Undiscounted Lease Liability (Details)
Loss Per Common Share
Loss Per Common Share (Details)
Other Expenses
Other Expenses (Details)
Other Expenses (Tables)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Related Party Transactions
Related Party Transactions (Details)
Related Party Transactions (Tables)
Share Capital
Share Capital (Tables)
Share Capital - Equity Warrants Narrative (Details)
Share Capital - Schedule Of Share Capital (Details)
Share Capital - Schedule Of Share Capital Footnotes (Details)
Share Capital - Summary Of Outstanding Warrants (Details)
Share-Based Compensation
Share-Based Compensation (Tables)
Share-Based Compensation - Disclosure Weighted Average Assumptions And Fair Value Of Options (Details)
Share-Based Compensation - Narrative (Details)
Share-Based Compensation - Schedule Of Number Of Other Equity Instruments (Details)
Share-Based Compensation - Schedule Of Stock Options And Weighted Average Exercise Prices (Details)
Share-Based Compensation - Schedule Of Stock Options Outstanding And Exercisable By Range Of Exercise Price (Details)
Significant Judgments, Estimates And Assumptions
Subsequent Events
Subsequent Events (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Narrative (Details)
Summary Of Significant Accounting Policies - Schedule Of Depreciation Rates (Details)
Warrant Derivative
Warrant Derivative (Tables)
Warrant Derivative - Narrative (Details)
Warrant Derivative - Reconciliation Of Change In Fair Value Of Warrant Derivative (Details)
Warrant Derivative - Summary Of Assumptions Used In The Black Scholes Option Pricing Model For Warrants (Details)
Ticker: ONCY
CIK: 1129928
Form Type: 20-F Annual Report
Accession Number: 0001129928-22-000017
Submitted to the SEC: Thu Mar 03 2022 4:55:08 PM EST
Accepted by the SEC: Thu Mar 03 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/oncy/0001129928-22-000017.htm